This observation contrasts with the effects of ABT-263 on fibrotic skin conditions, such as scleroderma and hypertrophic scars, where the treatment typically reduces collagen expression and targets αSMA-positive myofibroblasts [14, 18]. Here, ACTA1 is linked to scleroderma.